Abstract
The amyloid-β (Aβ) peptide is the principal components of the senile plaques found in the brains of patients with Alzheimers disease (AD). The poorly soluble 40-42 amino acid peptide, formed from the cleavage of the Ab precursor protein (APP) by two proteases, is believed to play a central role in the pathogenesis of AD. β-Secretase (memapsin 2, BACE1), a membrane-anchored aspartic protease, is responsible for the initial step of APP cleavage leading to the generation of Aβ. Identification and structural determination of β-secretase have established it to be a primary drug target for AD therapy and stimulated active studies on the inhibitors of this protease. Here we review more recent developments in the design and testing of structure-based β-secretase inhibitors.
Keywords: Alzheimer's disease, amyloid-β peptide, β-amyloid precursor protein, β-Secretase, Memapsin 2, aspartyl protease inhibitors, BACE-1, neurodegenerative disease, drug development
Current Topics in Medicinal Chemistry
Title: Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimers Disease
Volume: 5 Issue: 16
Author(s): Aurn K. Ghosh, Nagaswamy Kumaragurubaran and Jordan Tang
Affiliation:
Keywords: Alzheimer's disease, amyloid-β peptide, β-amyloid precursor protein, β-Secretase, Memapsin 2, aspartyl protease inhibitors, BACE-1, neurodegenerative disease, drug development
Abstract: The amyloid-β (Aβ) peptide is the principal components of the senile plaques found in the brains of patients with Alzheimers disease (AD). The poorly soluble 40-42 amino acid peptide, formed from the cleavage of the Ab precursor protein (APP) by two proteases, is believed to play a central role in the pathogenesis of AD. β-Secretase (memapsin 2, BACE1), a membrane-anchored aspartic protease, is responsible for the initial step of APP cleavage leading to the generation of Aβ. Identification and structural determination of β-secretase have established it to be a primary drug target for AD therapy and stimulated active studies on the inhibitors of this protease. Here we review more recent developments in the design and testing of structure-based β-secretase inhibitors.
Export Options
About this article
Cite this article as:
Ghosh K. Aurn, Kumaragurubaran Nagaswamy and Tang Jordan, Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimers Disease, Current Topics in Medicinal Chemistry 2005; 5 (16) . https://dx.doi.org/10.2174/156802605775009711
DOI https://dx.doi.org/10.2174/156802605775009711 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The UDP-Glucuronosyltransferases as Oligomeric Enzymes
Current Drug Metabolism Selective Estrogen Receptor Modulators (SERMs): Effects on Multiple Organ Systems
Current Medicinal Chemistry Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Recent Patents on Inflammation & Allergy Drug Discovery PET and SPECT Radiotracers for Alzheimer's Disease
Current Medicinal Chemistry Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Endophenotypes and Biological Markers of Schizophrenia: From Biological Signs of Illness to Novel Treatment Targets
Current Pharmaceutical Design Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets A Pharmacological Review of Five Widely Used Traditional Medicinal Plants for Sedative-Hypnotic Effects in Bangladesh
Current Traditional Medicine Physicochemical Assessment of Branded and Generic Linezolid Injection from Different Pharmaceutical Manufacturers
Current Pharmaceutical Analysis Immunotherapy with Peptides in Systemic Lupus Erythematosus
Current Medicinal Chemistry Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
CNS & Neurological Disorders - Drug Targets Computational Approaches to Screen Candidate Ligands with Anti- Parkinson’s Activity Using R Programming
Current Topics in Medicinal Chemistry Chemical and Medicinal Versatility of Substituted 1,4-Dihydropyridines
Current Bioactive Compounds Lewy Bodies: A Spectator or Salient Killer?
CNS & Neurological Disorders - Drug Targets Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Functional Peptides and Small Molecules in Medicinal Chemistry-Part II
Current Topics in Medicinal Chemistry Non-peptide CRF-Receptor Antagonists: Allosterism, Kinetics and Translation to Efficacy in Human Disease
Current Molecular Pharmacology Microwave Assisted Prospective Synthesis of New 5-Arylidene Rhodanine Derivatives Bearing a 3-[4-(3-Aminopropyl)piperazin-1-yl]propyl Side Chain
Current Microwave Chemistry